Study of Lorlatinib in ROS1 Rearranged NSCLC
NCT03612154 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2022-04-06
Summary
This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.
Conditions
- Nonsmall Cell Lung Cancer
Interventions
- DRUG
-
Lorlatinib
Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
Sponsors & Collaborators
-
National Cancer Center, Korea
lead OTHER_GOV
Principal Investigators
-
Ji-Youn Han, MD.Ph.D. · National Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-02
- Primary Completion
- 2022-12-31
- Completion
- 2023-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
NCT02927340 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
NCT06092086 ·Status: RECRUITING ·Phase: PHASE2
-
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
NCT04127110 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
NCT04111705 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
NCT03909971 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC
NCT06690541 ·Status: NOT_YET_RECRUITING
-
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT03178071 ·Status: NO_LONGER_AVAILABLE
-
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
NCT04541706 ·Status: COMPLETED ·Phase: PHASE4
-
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
NCT06487078 ·Status: RECRUITING ·Phase: NA
-
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
NCT01221077 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
NCT01310036 ·Status: COMPLETED ·Phase: PHASE2
-
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
NCT06858410 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04621188 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
NCT01470716 ·Status: UNKNOWN ·Phase: PHASE2
-
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
NCT06893354 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
NCT06361589 ·Status: RECRUITING
-
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
NCT06156527 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
NCT01230710 ·Status: COMPLETED ·Phase: PHASE4
-
Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC
NCT06904547 ·Status: NOT_YET_RECRUITING
-
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
NCT03126799 ·Status: UNKNOWN ·Phase: PHASE2
-
Lorlatinib Continuation Study
NCT05144997 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4